Merck extends Vioxx settlement deadline
Executive Summary
Merck is extending to June 30 the deadline for eligible claimants to enroll in the Vioxx settlement agreement. Under the agreement, Merck agreed to pay a fixed amount of $4.85 billion to cover 45,000 to 50,000 heart attack and stroke claims (1"The Pink Sheet," Nov. 12, 2007, p. 11). The deal is contingent on participation of 85 percent of all plaintiffs with pending and tolled claims against the company. Merck said that as of March 31, it appears that at least 94.5 percent of eligible claims in each category had initiated enrollment
You may also be interested in...
Merck’s Novel Vioxx Settlement May Set Standard To Resolve Litigation
Merck crafted extraordinary terms in its $4.85 billion agreement to resolve the bulk of Vioxx litigation, which analysts are heralding as a good result for the company
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.